Public Genomics Data Needed, FDA, NIH Say; Patent Protection Still An Issue
Executive Summary
NIH expects its small molecule database to provide drug development candidates to small biotechnology firms and disease foundations pursuing orphan indications
You may also be interested in...
NIH Move To Consolidate Translational Programs Is Not The Big Shakeup It's Made Out To Be, Agency Says
The National Institutes of Health's proposed National Center for Advancing Translational Sciences reflects neither a shakeup of existing NIH programs nor any intent to create an agency that functions like a drug company, NIH officials say.
NIH Move To Consolidate Translational Programs Is Not The Big Shakeup It's Made Out To Be, Agency Says
The National Institutes of Health's proposed National Center for Advancing Translational Sciences reflects neither a shakeup of existing NIH programs nor any intent to create an agency that functions like a drug company, NIH officials say.
Biotechs Must Work With NIH To Tackle “Complexity,” NIH Director Tells BIO
Pharmaceutical and biotech companies need to work with NIH to put new research tools into the public domain, National Institutes of Health Director Elias Zerhouni, MD, told the recent Biotechnology Industry Organization investor conference in New York